**FOR IMMEDIATE RELEASE**

# Epihunter and Bright Minds Biosciences Launch Strategic Collaboration to Advance Clinical Research in Drug-Resistant Epilepsy

*Real-time seizure detection technology from Epihunter to be used in Phase 2 trial of Bright Minds Biosciences' lead investigational drug BMB-101*

**[Hasselt, Belgium and Vancouver, Canada – June 24, 2025]** – Epihunter, a leading digital health company focused on real-time brain monitoring solutions for neurological disorders, today announced a strategic collaboration with Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG), a biotechnology company developing targeted serotonergic therapeutics. Bright Minds will integrate Epihunter's real-time wearable EEG technology into its ongoing Phase 2 BREAKTHROUGH clinical trial of BMB-101, a novel investigational drug for drug-resistant epilepsy.

The Epihunter system will enable continuous, at-home seizure monitoring for participants in both the Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE) arms of the study. This collaboration marks a significant step forward in leveraging real-world, objective seizure data to complement traditional seizure diaries and enhance the evaluation of clinical outcomes.

> "This collaboration is a milestone in our mission to make invisible epileptic seizures and epileptiform brain activity visible," said **Tim Buckinx, Founder and CEO of Epihunter**. "We're proud that our technology will support Bright Minds' clinical research and help advance a promising therapy for people with epilepsy and their families in urgent need of new treatment options. This partnership affirms the critical role of wearable EEG in delivering better data and better outcomes."

> "Accurate seizure tracking has long been a challenge, particularly in absence epilepsy," said **Ian McDonald, CEO and Co-founder of Bright Minds Biosciences**. "Epihunter's wearable technology combines a discrete EEG headband with a smartphone app, providing seamless, data collection and real-time analysis and cloud-based reporting. Using this innovative solution at home enables a more precise and continuous understanding of seizure activity and drug effect of BMB-101, which is critical for evaluating therapeutic benefit in patients with drug-resistant epilepsy."

Epihunter's solution has been clinically validated in a blinded, multi-center trial (NCT04615442), demonstrating a median sensitivity per participant of 92.9% for automated absence seizure detection. In recognition of its innovative approach, Epihunter was recently awarded the 2025 Epilepsy Foundation Shark Tank grant to further develop its EEG-based solutions.

---

**About Epihunter**

Epihunter was founded with the goal of providing groundbreaking digital solutions for the challenges associated with neurological disorders. The company's mission is to enable people with brain disorders to participate more fully in society. It is committed to developing technologies that improve daily life while contributing to research and treatment. Their digital products innovatively combine wearable brain sensors with real-time artificial intelligence for real-time digital therapeutic and non-therapeutic interventions. Such interventions aim to increase the quality of life for the person with the disorder, generate data for faster diagnosis and optimized treatment, and provide critical insights for new digital and pharmaceutical therapy modalities. While epihunter will remain the name for its epilepsy product pipeline, the name farow will be used for its expansion into other brain disorders too.

Learn more at www.epihunter.com.

---

**About Bright Minds Biosciences**

Bright Minds is a biotechnology company focused on developing targeted serotonin receptor agonists for the treatment of CNS disorders including epilepsy and depression. Its lead drug candidate, BMB-101, is a 5-HT2C Gq-biased agonist designed to provide sustained seizure relief. For more information, visit www.brightmindsbio.com.

---

**Media Contact:**

*Tim Buckinx*
Founder & CEO, Epihunter
info@epihunter.com